| FLORIDA |
Location: Deerfield Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jose De La Gandara
877-379-3718
Back
to Top |
Location: Delray Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Mark Brody
877-379-3718
Back
to Top |
Location: Delray Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Mark Brody
877-379-3718
Back
to Top |
Location: Destin
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Elizabeth Roberson
877-379-3718
Back
to Top |
Location: Florida
University of Florida – Brain Imaging Rehabilitation and Cognition Lab
Trial Title and Description:An fMRI Model of Naming in Alzheimer’s Disease
Do you or someone you know have Alzheimer’s disease?
Participants are needed for a research study to help us better understand language problems in Alzheimer’s disease. Participants must be right handed, native English language speakers, and able to undergo an MRI scan. Compensation will be provided for undergoing the MRI scan. If interested please call the University of Florida at (352 ) 273-5249.
Enrollment Status: Recruiting
Study Dates:
Condition:
Age Eligibility:
Gender Eligibility:
Enrollment Goal:
Clinical Identifier:
Study Phase:
Study Type:
Sponsor:
Contact Information:
BIRC Lab
(352) 273-5249
Back to Top |
Location: Hallandadle Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Beth Safirstein
877-379-3718
Back
to Top |
Location: Hialeah
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Miguel Flores
877-379-3718
Back
to Top |
Location: Jacksonville
Baptist
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Sally Coxwell
904-202-7073
sallybrci@aol.com
Back
to Top |
Location: Melbourne
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Thomas Hoffman
877-379-3718
Back
to Top |
Location: Miami
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Mario
Cuervo
877-379-3718
Back
to Top |
Location: Miami Beach
Wien Center for Clinical Research
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Peggy Roberts
305-674-2424
proberts@msmc.com
For more information, visit www.gapstudy.com
Back to Top |
Location: Miami Beach
Wien
Center, Mount Sinai Medical Center
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Peggy Roberts
305-674-2424
proberts@msmc.com
Ranjan Duara
Back
to Top |
Location: Miami Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Ranjan Duara
877-379-3718
Back
to Top |
Location: Naples
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Anchor Research Center
Candy Pewanick
239-643-8805
www.KiokuStudy.com
Back to Top |
Location: North Palm Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Walter
Martinez
877-379-3718
Back
to Top |
Location: Plantation
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Richard McLean
877-379-3718
Back
to Top |
Location: Sarasota
Roskamp Institute Memory Clinic
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Cheryl Rindfleisch
941-256-8018, ext 356
crindfleisch@rfdn.org
For more information, visit www.gapstudy.com
Back to Top
|
Location: Sarasota
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Roland
Aung-din
877-379-3718
Back
to Top |
Location: Sunrise
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Richard
Singer
877-379-3718
Back
to Top |
Location: Tampa
University of South Florida, Tampa / Suncoast
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Barbara Luhn
813-974-4355
bluhn@health.usf.edu
Back to Top |
Location: Call for details
Trial Title and Description: A study of V950 in People with
Alzheimer's Disease-
The purpose of this study is to test the safety,
tolerability and immune response to an investigational
vaccine, V950.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00464334
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Merck
Contact Information:
Trial
Manager
888-577-8839
Back
to Top |
| GEORGIA |
Location: Decatur
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Michael
Norman
877-379-3718
Back
to Top |
Location: Tucker
Kaiser
Southeast Permanente Medical Group
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Carol A. Mayers
770-496-3634
Back
to Top |
| IDAHO |
Location: Middleton
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Leslie
Taylor
877-379-3718
Back
to Top |
| INDIANA |
Location: Fort Wayne
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Fen-lei Chang
877-379-3718
Back
to Top |
Location: Indianapolis
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Agewell
Lori Rawlings, RN
317-846-9792 ext. 103
www.KiokuStudy.com
Back to Top |
Location: Indianapolis
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Ann Marie Hake
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: Raloxifene for Women with Alzheimer's
Disease-
The purpose of this study is to determine whether
Raloxifene, a selective estrogen receptor modulator,
improves cognitive function in women with Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: August
2006
Condition: Alzheimer's
disease
Age Eligibility: 60 and
above
Gender Eligibility: Female
Enrollment Goal: 72
Clinical Identifier: NCT00368459
Study Phase: Phase
2
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Victor Henderson
650-498-5232
asye@stanford.edu
Sheryl Lynch
317-278-8307
slynch@iupui.edu
Back
to Top |
| IOWA |
Location: Ames
Bliss Cancer
Center/McFarland Clinic
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Janet C. Mannetter
515-239-2621
mannetter@mgmc.com
Back
to Top |
Location: Cedar Rapids
Cedar
Rapids CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kathy Fleming
319-363-2690
Back
to Top |
Location: Davenport
Genesis
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Not yet r
ecruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu
Back
to Top |
Location: Des Moines
Iowa
Oncology Research Association
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Mary Loots
515-244-7586
Back
to Top |
Location: Iowa City
University of Iowa
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Karen Ekstam-Smith
319-353-5158
karen-ekstam@uiowa.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: Sioux City
Siouxland
Hematology-Oncology Associates
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Pamela J. Mears
712-252-9334
Back
to Top |
| KANSAS |
Location: Kansas City
University of Kansas
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Cherie Parker
913-588-0602
cparker@kumc.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: Kansas
City
University of Kansas Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Scott Stanley
913-588-3124
sstanley@kumc.edu
Back
to Top |
Location: Topeka
Stormont-Vail
Health Care/Cotton O'neil Clinic
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Anita S. Leonard
785-354-0540
Back
to Top |
Location: Wichita
Wichita
CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Marge J. Good
316-268-5696
Back
to Top |
| KENTUCKY |
Location: Ashland
Our Lady of
Bellefonte Hospital Inc.
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Barb Payne
606-833-3253
bpayne@olbh.com
Back
to Top |
Location: Lexington
University of Kentucky
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Sarah Carr
859-257-1412, ext 289
sacarr3@email.uky.edu
For more information, visit www.gapstudy.com
Back to Top |
Location: Lexington
University
of Kentucky
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Jeffrey Howe
859-257-6507
jnhowe0@uky.edu
Kathy Grossman
859-257-5562
kgros2@email.uky.edu
Gregory Jicha
Back
to Top |
Location: Lexington
University
of Kentucky Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
PREADVISE Coordinator
Center
866-846-1412
preadvise@lsv.uky.edu
Back
to Top |
Location: Lexington
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Not yet recruiting
859-296-1922
Craig Knox
Back
to Top |
Location: Louisville
Louisville VA Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002 Expected Completion: August 2013
Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional
Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Patricia A. Quiggins
502-895-3401 ext. 5131
paguig01@louisville.edu
Back to Top |
